Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...

Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.